Familial medullary thyroid carcinoma with noncysteine RET mutations: Phenotype-genotype relationship in a large series of patients

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 8, 2001, Pages 3746-3753

  Niccoli Sire, Patricia ^a   Murat, Arnaud ^b   Rohmer, Vincent ^d   Franc, Sylvia ^e   Chabrier, Gerard ^f   Baldet, Line ^g   Maes, Beatrice ^h   Savagner, Frederique ^d   Giraud, Sophie ⁱ   Bezieau, Stephane ^c   Kottler, Marie Laure ^j   Morange, Sophie ^a   Conte Devolx, Bernard ^a  

^a TIMONE HOSPITAL   (France)

^b Service d'Endocrinologie   (France)

^c Laboratoire Genetique Moleculaire   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e AVICENNE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h INSTITUT JEAN GODINOT   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; GENE PRODUCT; PROTEIN RET; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CELL HYPERPLASIA; CLINICAL ARTICLE; EXON; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MALE; NODULAR GOITER; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA;

EID: 17944370976     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.8.7767     Document Type: Article

References (44)

1. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: Report of the International RET Mutation Consortium
2. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis
3. Genetic testing in medullary thyroid carcinoma syndromes: Mutation types and clinical significance
4. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma
5. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
6. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
7. Mutations of the RET protooncogene in German multiple endocrine neoplasia families: Relation between genotype and phenotype
8. RET proto-oncogene mutations in the French MEN 2A and FMTC families
9. Germline mutation of RET codon 883 in two cases of de novo MEN 2B
10. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation
11. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B
12. Clinical management of multiple endocrine neoplasia type 2 - Is there an additional clinical phenotype?
13. Two germline missense mutations at codons 804 and 806 of the RET protooncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation
14. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A
15. A duplication of 9 base pairs in the critical cysteine rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A
16. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET proto-oncogene
17. Afro-American kindred with a new point mutation in RET oncogene
18. Analysis of RET proto-oncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinoma
19. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): Mutation analysis in Japanese patients with MTC
20. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC
21. RET mutations in exons 13 and 14 of FMTC patients
22. Familial medullary thyroid carcinoma: Not a distinct entity? Genotype-phenotype correlation in a large family
23. A new hot spot for mutations in the the RET protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A
24. A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma
25. A novel point mutation in the intracellular domain of the RET proto-oncogene in a family with medullary thyroid carcinoma
26. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma
27. Early or prophylactic thyroidectomy in NEM2/FMTC gene carriers: Results in 71 thyroidectomized patients
28. Sex related C-cell hyperplasia in the normal human thyroid: A quantitative autopsy study
29. Interest of routine measurement of serum calcitonin in a large series of thyroidectomized patients
30. Somatic and MEN2A de novo mutations identified in the RET protooncogene by screening of sporadic MTCs
31. RET protooncogene point mutations in sporadic neuroendocrine tumors
32. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain
33. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2
34. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2
35. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes
36. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations
37. Biological and biochemical properties of RET with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma
38. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A
39. Pheochromocytoma in multiple endocrine neoplasia type 2: European study
40. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene
41. Pheochromocytoma in multiple endocrine neoplasia type 2: A prospective study
42. Multiple endocrine neoplasia type 2B: More than an endocrine disorder
43. Pre-operative calcitonin levels are predictive of tumor size and post-operative calcitonin normalization in medullary thyroid carcinoma